The role of bisphosphonates in the treatment of bone metastases - The U.S. experience

Supportive Care in Cancer

Volumn 4, Issue 3, 1996, Pages 213-217

  Harvey, Harold A ^a   Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Aredia; Bisphosphonates; Bone metastases; Pain; Skeleton related events

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; PLACEBO;

ARTICLE; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PAIN; PALLIATIVE THERAPY; PATHOLOGIC FRACTURE; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; UNITED STATES;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; INJECTIONS, INTRAVENOUS; MALE; MULTIPLE MYELOMA; OSTEOCLASTS; PAIN; PALLIATIVE CARE; PLACEBOS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SPINAL CORD COMPRESSION; UNITED STATES;

EID: 0030144847     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01682343     Document Type: Article

References (27)

1. Albright JA, Gillespie TE, Butaud TR (1986) Treatment of bone metastases. Semin Oncol 7:418-434
2. Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer 72:3443-3452
3. Body JJ (1992) Bone metastases and tumor-induced hypercalcemia. Current Opin Oncol 4:624-631
4. Clemens MR, Fessele K, Heim ME (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66:141-146
5. Coleman RE (1994) Therapeutic use of bisphosphonates in oncology. BMJ 309:1233
6. Coleman RE, Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19:79-103
7. Coleman RE, Rubens RD (1985) Bone metastases and breast cancer. Cancer Treat Rev 12:251-270
8. Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61-66
9. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized muticenter phase III trial. Ann Oncol 5 [Suppl 7]: S41-44
10. Coyler RA (1986) Surgical stabilization of pathologic neoplastic fractures. Curr Probl Cancer 10:118-168
11. Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591-598
12. Galasko CSB (1982) Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169:20-27
13. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949-2955
14. Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751
15. Holten-Verzantvoort AT van, Zwinderman AH, Aaronson NK, Hermans J, Emmerik B van, Dam FS van, Bos B van den, Bijvoet OL, Cleton FJ (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544-549
16. Holten-Verzantvoort AT van, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498
17. Hortobagyi GN, Libshitz HI, Seabold JE (1984) Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy. Cancer 53:577-582
18. Lipton A (1994) The role of pamidronate. Ann Oncol 5 [Suppl 7]: S25-26
19. Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, Seaman J (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 5 [Suppl 7]: S31-35
20. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, Pannuti F (1991) Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97-101
21. Papapoulos SE, Holten-Verzantvoort AT van (1992) Modulation of tumour-induced bone resorption by bisphosphonates. J Steroid Biochem Mol Biol 43:131-136
22. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
23. Shapiro CL (1994) Bisphosphonates in breast cancer patients with skeletal metastases. Hematol Oncol Clin North Am 8:153-163
24. Thiebaud D, Leyvraz S, Fliedner V von, Perey L, Cornu P, Thiebaud S, Burckhardt P (1991) Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37-41
25. Thurlimann B (1994) Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Ann Oncol 5 [Suppl 7]: 545-547
26. Tyrell CJ, Collinson M, Madsen EL, Ford JM, Coleman T (1994) Intravenous pamidronate: infusion rate and safety. Ann Oncol 5 [Suppl 7]: S27-29
27. Wasan HS, Waxman J (1993) Clodronate for multiple myeloma. Lancet 341:175-176